Human Blood Plasma Fractionation Market Size, Share, Growth, and Industry Analysis, By Type (Immune Globulin,Coagulation Factor,Albumin,Others), By Application (Hospital,Retail Pharmacy,Others), Regional Insights and Forecast to 2035

Human Blood Plasma Fractionation Market Overview

Global Human Blood Plasma Fractionation Market size is anticipated to be worth USD 40655.7 million in 2026 and is expected to reach USD 78760.72 million by 2035 at a CAGR of 7.6%.

Human Blood Plasma Fractionation Market Analysis shows that plasma fractionation is a complex biopharmaceutical process used to separate plasma proteins into therapeutic products such as albumin, immunoglobulins, and coagulation factors. Global plasma collection exceeded 60 million liters annually by 2024, with more than 75% of this volume processed through industrial fractionation facilities. The Human Blood Plasma Fractionation Market Research Report indicates that over 900 plasma collection centers operate globally, including more than 700 centers dedicated to plasmapheresis. Plasma-derived medicines are used in treatment protocols for more than 100 rare diseases, including hemophilia, primary immunodeficiency disorders, and chronic inflammatory demyelinating polyneuropathy affecting approximately 6 in 100000 individuals.

Human Blood Plasma Fractionation Industry Analysis shows that immunoglobulins account for nearly 55% of plasma-derived therapies used worldwide. More than 300 therapeutic plasma-derived products are approved globally, and over 40 fractionation plants operate across North America, Europe, and Asia. Human Blood Plasma Fractionation Market Insights indicate that plasma-derived medicines are used by more than 500000 patients annually in immunology and neurology applications. Albumin products represent approximately 25% of plasma protein therapeutics used in clinical settings. Human Blood Plasma Fractionation Market Trends highlight increasing demand driven by aging populations, with over 770 million individuals globally aged above 65 years in 2024, increasing the prevalence of chronic diseases treated with plasma-derived therapies.

The United States represents the largest contributor to the Human Blood Plasma Fractionation Market Size, accounting for approximately 70% of global plasma collection volume. More than 530 licensed plasma collection centers operate across 40 states, supporting annual plasma collection exceeding 40 million liters. The Human Blood Plasma Fractionation Market Outlook in the United States is driven by high donation frequency, with eligible donors permitted to donate plasma up to 104 times annually through plasmapheresis programs.

Human Blood Plasma Fractionation Market Insights show that over 30 fractionation and plasma processing facilities operate in the United States, supplying plasma-derived therapies to more than 300000 patients annually. Immunoglobulin therapy utilization has increased significantly, with more than 120000 patients receiving intravenous immunoglobulin treatment in 2024. The Human Blood Plasma Fractionation Market Research Report highlights that hemophilia affects nearly 33000 individuals in the United States, requiring consistent plasma-derived clotting factor therapies.

Key Findings

• Key Market Driver: Immunoglobulin demand represents 55% therapeutic usage while plasma collection expansion increased donor participation by 18% globally
• Major Market Restraint: Plasma supply shortages impact 15% therapy demand while donor eligibility screening rejects nearly 20% potential donors
• Emerging Trends: Chromatography purification adoption reached 62% while automated monitoring technologies improved plasma protein recovery efficiency by 15%
• Regional Leadership: North America contributes 70% global plasma collection while United States produces nearly 65% immunoglobulin supply
• Competitive Landscape: Top five manufacturers control 68% fractionation capacity while twelve companies produce over 80% plasma therapeutics
• Market Segmentation: Immunoglobulin holds 55% share while albumin accounts for 25% and coagulation factors contribute nearly 15%
• Recent Development: Manufacturing capacity expanded by 12% globally while new plasma collection centers increased worldwide supply availability by 18%.

Human Blood Plasma Fractionation Market Latest Trends

Human Blood Plasma Fractionation Market Trends are evolving rapidly as plasma-derived therapies become essential treatments for immune deficiencies, neurological disorders, and bleeding disorders. Global plasma collection increased from approximately 50 million liters in 2019 to more than 60 million liters in 2024, reflecting an increase of nearly 20% in collection capacity. More than 100 countries utilize plasma-derived therapeutics, and over 500000 patients globally rely on immunoglobulin therapy annually. Technological advancements in fractionation processes are significantly improving protein yield and purification efficiency. Chromatography-based fractionation systems have increased plasma protein recovery rates by nearly 15% compared with traditional ethanol fractionation techniques developed in the 1940s. Modern fractionation facilities process between 1.5 million and 2.5 million liters of plasma annually, producing albumin, immunoglobulins, and clotting factors in large-scale batches exceeding 5000 liters per production cycle.

The increasing prevalence of immune-related disorders represents a major factor shaping Human Blood Plasma Fractionation Market Growth. Primary immunodeficiency disorders affect approximately 6 million individuals worldwide, yet only about 30% of diagnosed patients receive immunoglobulin therapy due to supply limitations. Neurological disorders such as chronic inflammatory demyelinating polyneuropathy affect nearly 5 per 100000 individuals globally, increasing demand for intravenous immunoglobulin treatments. Another major trend is the expansion of plasma collection infrastructure. Between 2020 and 2024, more than 200 new plasma donation centers were established globally, with North America accounting for nearly 60% of these facilities. Plasmapheresis technology enables donors to donate plasma twice per week, increasing annual plasma supply capacity by nearly 35% compared with traditional whole blood donation systems.

Human Blood Plasma Fractionation Market Dynamics

DRIVER

"Rising demand for plasma-derived therapies in immunology and hematology"

The Human Blood Plasma Fractionation Market Growth is strongly driven by increasing prevalence of immune disorders and bleeding disorders worldwide. Approximately 6 million individuals globally are diagnosed with primary immunodeficiency diseases, while hemophilia affects nearly 400000 patients worldwide. Immunoglobulin therapy demand increased by nearly 18% between 2020 and 2024 due to growing clinical applications in neurology and autoimmune diseases. Hospitals administer more than 120 million grams of immunoglobulin products annually. Plasma-derived albumin is widely used in liver disease treatment, affecting nearly 1.5 billion individuals globally with chronic liver conditions. Increasing healthcare access across emerging markets has also expanded plasma-derived therapy usage by nearly 22% during the last five years.

RESTRAINT

"Limited plasma donor availability and strict regulatory frameworks"

The Human Blood Plasma Fractionation Market faces significant restraints due to dependence on voluntary plasma donors. Approximately 70% global plasma supply originates from the United States, creating supply concentration risks. Many countries restrict paid plasma donation programs, limiting collection capacity by nearly 40% compared with the United States. Plasma fractionation facilities require regulatory approvals that may take 3 to 5 years before operational authorization. Additionally, plasma collection procedures require strict screening protocols where nearly 20% of potential donors are rejected due to medical eligibility criteria. These limitations create periodic plasma shortages, particularly for immunoglobulin therapies where demand exceeds supply by approximately 15% in several healthcare systems.

OPPORTUNITY

"Expansion of plasma fractionation capacity in emerging economies"

Emerging markets represent a major Human Blood Plasma Fractionation Market Opportunity due to expanding healthcare infrastructure and increasing plasma collection initiatives. Countries in Asia-Pacific have established more than 120 new plasma collection centers between 2021 and 2024. China alone operates over 250 plasma donation stations supporting domestic fractionation plants. Government initiatives have increased plasma collection volumes by nearly 30% across emerging healthcare systems. Local manufacturing capacity expansion is also increasing global supply stability, with new fractionation plants capable of processing more than 1 million liters of plasma annually. Growing demand for albumin in intensive care units and surgical procedures is increasing clinical usage rates by nearly 12% annually in developing healthcare markets.

CHALLENGE

"Complex manufacturing processes and long production cycles"

Human Blood Plasma Fractionation Industry Analysis shows that plasma fractionation involves complex multi-step purification processes requiring more than 6 to 9 months from plasma collection to finished product distribution. Each plasma batch undergoes more than 10 purification stages including cryoprecipitation, filtration, and chromatography. Viral inactivation procedures such as solvent-detergent treatment and pasteurization are mandatory, increasing production costs by nearly 20%. Plasma fractionation plants require highly specialized infrastructure including cryogenic storage systems capable of storing more than 100000 liters of plasma. Facility construction and regulatory certification may require investments exceeding 5 years of development time, limiting rapid expansion of manufacturing capacity worldwide.

Human Blood Plasma Fractionation Market Segmentation

Human Blood Plasma Fractionation Market Segmentation includes therapeutic plasma proteins distributed across multiple medical applications. Immunoglobulins represent approximately 55% of global plasma-derived therapy utilization, albumin accounts for nearly 25%, and coagulation factors contribute about 15%, while other proteins represent approximately 5% clinical demand worldwide.

BY TYPE

Immune Globulin: Immune globulin products dominate the Human Blood Plasma Fractionation Market Share, accounting for nearly 55% of plasma-derived therapeutics globally. More than 500000 patients worldwide receive intravenous or subcutaneous immunoglobulin therapies annually for immune deficiency disorders. Approximately 6 million individuals globally suffer from primary immunodeficiency diseases requiring lifelong immunoglobulin treatment. Neurological disorders such as Guillain-Barre syndrome affect nearly 100000 individuals worldwide, increasing immunoglobulin demand in hospital settings. More than 70 immunoglobulin formulations are approved across major regulatory markets. Hospitals administer immunoglobulin doses ranging between 300 mg/kg and 2000 mg/kg per treatment cycle, resulting in global consumption exceeding 120 million grams annually.

Coagulation Factor: Coagulation factors represent approximately 15% of plasma-derived therapeutics within the Human Blood Plasma Fractionation Market Size. Hemophilia affects nearly 400000 individuals globally, with hemophilia A accounting for approximately 80% of cases and hemophilia B representing nearly 20%. Plasma-derived factor VIII and factor IX products remain essential treatments in many healthcare systems where recombinant therapies are limited. More than 70% hemophilia patients require prophylactic treatment with clotting factor infusions administered two to three times per week. Plasma-derived clotting factors also support treatment for von Willebrand disease affecting approximately 1% of the global population. Annual plasma requirement for clotting factor production exceeds 10 million liters globally.

Albumin: Albumin represents approximately 25% of therapeutic plasma proteins within the Human Blood Plasma Fractionation Industry Analysis. Albumin products are widely used in liver disease management, burns treatment, and surgical procedures. Chronic liver disease affects more than 1.5 billion individuals globally, creating substantial demand for albumin therapy in hospitals and intensive care units. Albumin solutions are commonly available in concentrations ranging from 5% to 25% for intravenous administration. More than 200 million vials of albumin products are distributed globally each year. Intensive care units administer albumin in approximately 35% of severe sepsis cases and nearly 25% of major trauma treatment protocols worldwide.

Others: Other plasma-derived products including alpha-1 antitrypsin, fibrinogen, and C1 esterase inhibitors represent nearly 5% of the Human Blood Plasma Fractionation Market Outlook. Alpha-1 antitrypsin deficiency affects approximately 1 in 2500 individuals worldwide, requiring plasma-derived augmentation therapy. Fibrinogen concentrates are used in trauma management where severe bleeding occurs in approximately 10% of major surgical procedures. C1 esterase inhibitor therapies are used in hereditary angioedema treatment affecting nearly 1 in 50000 individuals globally. More than 20 specialized plasma protein products are manufactured through fractionation technologies. These therapies collectively serve approximately 200000 patients worldwide suffering from rare plasma protein deficiency disorders.

BY APPLICATION

Hospital: Hospitals represent the largest application segment within the Human Blood Plasma Fractionation Market, accounting for nearly 60% of plasma-derived therapy administration. More than 250000 hospitals worldwide administer plasma-derived therapeutics for immune disorders, liver disease, and trauma management. Intensive care units administer albumin in approximately 35% of severe sepsis cases. Hemophilia treatment centers located within hospitals treat nearly 400000 patients worldwide requiring clotting factor infusions. Immunoglobulin therapies are frequently administered in neurology departments treating conditions such as Guillain-Barre syndrome affecting nearly 100000 patients globally. Hospital pharmacies store plasma-derived therapeutics in controlled temperature environments between 2°C and 8°C to maintain product stability.

Retail Pharmacy: Retail pharmacies represent approximately 25% of plasma-derived therapeutic distribution in the Human Blood Plasma Fractionation Market. Subcutaneous immunoglobulin therapies enable home-based treatment for nearly 150000 patients globally suffering from primary immunodeficiency diseases. Retail pharmacies distribute more than 80 million immunoglobulin therapy doses annually. Specialty pharmacy networks manage plasma-derived product distribution in more than 40 countries. Prescription-based plasma-derived therapies require cold chain logistics systems maintaining temperatures below 8°C during transportation. Retail pharmacies increasingly support outpatient treatment programs where nearly 30% immunoglobulin therapy patients receive home infusion therapy administered through trained healthcare professionals.

Others: Other application channels including specialty clinics and blood disorder treatment centers account for nearly 15% of the Human Blood Plasma Fractionation Market Insights. More than 1400 hemophilia treatment centers operate worldwide providing clotting factor therapy and patient monitoring. Neurology specialty clinics administer immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy affecting approximately 5 per 100000 individuals globally. Plasma exchange therapy procedures are conducted in more than 2000 specialized clinics worldwide. Blood disorder treatment centers support long-term management of rare plasma protein deficiency disorders affecting nearly 200000 patients globally. These specialized facilities maintain plasma-derived therapeutic inventories exceeding 500 treatment units per clinical center.

Human Blood Plasma Fractionation Market Regional Outlook

The Human Blood Plasma Fractionation Market Outlook demonstrates strong regional variations driven by plasma donation policies, healthcare infrastructure, and therapeutic demand. North America accounts for approximately 70% of global plasma collection capacity, followed by Europe with nearly 20%, Asia-Pacific with approximately 8%, and Middle East & Africa contributing nearly 2%.

NORTH AMERICA

North America dominates the Human Blood Plasma Fractionation Market Share with nearly 70% of global plasma collection capacity. The United States alone contributes approximately 65% of immunoglobulin supply worldwide. More than 530 plasma collection centers operate across North America, supporting annual plasma collection exceeding 40 million liters. Canada operates approximately 50 plasma collection facilities contributing nearly 1.5 million liters annually. North America hosts more than 20 large-scale plasma fractionation plants capable of processing over 25 million liters of plasma annually. Plasma-derived therapies are administered to nearly 350000 patients annually across hematology, immunology, and neurology treatment programs within North American healthcare systems.

EUROPE

Europe accounts for approximately 20% of global Human Blood Plasma Fractionation Market Size supported by strong healthcare infrastructure and regulatory frameworks. More than 200 plasma donation centers operate across Germany, Austria, Czech Republic, and Hungary. Germany collects nearly 3 million liters of plasma annually representing the largest European contribution. Approximately 12 plasma fractionation plants operate across Europe processing more than 10 million liters annually. Immunoglobulin therapy demand increased by nearly 12% across European healthcare systems between 2021 and 2024. More than 120000 patients in Europe receive plasma-derived immunoglobulin therapies annually for immune deficiency and neurological disorders.

ASIA-PACIFIC

Asia-Pacific represents approximately 8% of global plasma fractionation capacity but shows significant expansion potential. China operates more than 250 plasma collection stations producing nearly 9000 tons of plasma annually. Japan and South Korea collectively operate approximately 40 plasma collection centers supporting domestic plasma supply. More than 15 plasma fractionation facilities operate across China, Japan, and India combined. Albumin therapy usage is particularly high in China where more than 60% of plasma-derived albumin consumption occurs in hospital intensive care units. Increasing healthcare investments across Asia-Pacific expanded plasma collection volumes by nearly 30% between 2020 and 2024.

MIDDLE EAST & AFRICA

Middle East & Africa account for nearly 2% of the Human Blood Plasma Fractionation Market Share due to limited plasma collection infrastructure. Approximately 20 plasma collection centers operate across the region primarily in Saudi Arabia, South Africa, and the United Arab Emirates. Plasma-derived therapeutic demand increased by nearly 10% between 2021 and 2024 due to rising prevalence of hemophilia and immune disorders. Regional healthcare systems import nearly 85% of plasma-derived medicines from North America and Europe. Government healthcare programs support treatment for approximately 15000 hemophilia patients across the Middle East and Africa.

List of Top Human Blood Plasma Fractionation Companies

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• RAAS
• CBPO
• Hualan Bio
• Tiantan Bio
• Shuanglin Bio
• Boya Bio
• Yuanda Shuyang
• Weiguang Bio
• Nanyue Bio
• KM Biologics

Top Two Companies with the Highest Market Share

• CSL operates over 300 plasma collection centers processing more than 15 million liters annually supporting global plasma-derived therapeutic supply.
• Grifols operates approximately 390 plasma donation centers and processes nearly 20 million liters of plasma annually worldwide.

Investment Analysis and Opportunities

Human Blood Plasma Fractionation Market Opportunities are expanding as pharmaceutical companies increase investments in plasma collection infrastructure and fractionation facilities. Between 2020 and 2024, more than 200 new plasma donation centers were established globally, increasing total global collection capacity by nearly 18%. Large-scale fractionation plants typically process between 1 million and 2.5 million liters of plasma annually. Construction of a single fractionation facility requires more than 50000 square meters of production space and advanced cryogenic storage systems capable of storing over 100000 liters of plasma simultaneously. Investment activity in plasma collection networks is particularly strong in North America and Europe. More than 60% of global plasma investment projects are concentrated in the United States due to favorable plasma donation regulations. Companies have expanded plasmapheresis programs enabling donors to donate plasma up to twice per week, increasing annual plasma collection capacity by nearly 35%. Approximately 80% of global immunoglobulin supply originates from plasma collected through these plasmapheresis programs.

Emerging economies represent a significant Human Blood Plasma Fractionation Market Opportunity. China has established more than 250 plasma donation stations supporting domestic fractionation capacity. India has increased plasma collection initiatives across major metropolitan healthcare centers where plasma demand increased by nearly 15% between 2021 and 2024. Government healthcare investments are supporting construction of new fractionation facilities capable of processing more than 500000 liters annually. Biopharmaceutical companies are also investing in advanced purification technologies to improve plasma protein yield. Chromatography-based fractionation systems improve protein recovery efficiency by nearly 15% compared with conventional ethanol fractionation. Automated purification systems now monitor more than 20 process parameters simultaneously, improving manufacturing productivity by approximately 12%.

New Product Development

Human Blood Plasma Fractionation Market Trends highlight rapid innovation in plasma-derived therapeutic development. More than 300 plasma-derived medicinal products are currently approved globally across immunology, hematology, and neurology therapeutic categories. Pharmaceutical companies are increasingly developing high-concentration immunoglobulin formulations enabling shorter infusion times and improved patient convenience. Subcutaneous immunoglobulin therapies represent a major product innovation segment. More than 20 subcutaneous immunoglobulin products are approved globally allowing patients to administer therapy at home. These products reduce hospital visits by nearly 40% for patients suffering from primary immunodeficiency diseases. High-concentration immunoglobulin solutions exceeding 20% protein concentration reduce infusion volumes by nearly 50% compared with traditional intravenous therapies.

Advancements in viral inactivation technologies have significantly improved safety profiles of plasma-derived medicines. Solvent-detergent treatment and nanofiltration systems remove viral contaminants smaller than 20 nanometers. These technologies reduce viral transmission risk by more than 99.99%. Plasma fractionation plants conduct more than 15 quality control tests during manufacturing processes before product release. New albumin formulations have also been developed to support intensive care treatment protocols. Albumin solutions with concentrations ranging from 5% to 25% are now used in trauma management and liver failure treatment affecting nearly 1.5 billion individuals globally with liver disease. More than 200 million albumin vials are distributed annually worldwide.

Five Recent Developments

• In 2023 CSL expanded plasma collection infrastructure by opening more than 25 new donation centers across North America increasing plasma collection capacity by approximately 12%.
• In 2024 Grifols increased global fractionation capacity by upgrading manufacturing facilities capable of processing nearly 2 million additional liters of plasma annually.
• In 2023 Takeda introduced a high-concentration immunoglobulin therapy reducing infusion time by nearly 35% compared with conventional intravenous treatments.
• In 2024 Octapharma expanded its plasma fractionation facility in Europe increasing annual processing capacity beyond 1 million liters of plasma.
• In 2025 Kedrion implemented automated chromatography purification systems improving plasma protein recovery efficiency by approximately 15%.

Report Coverage of Human Blood Plasma Fractionation Market

Human Blood Plasma Fractionation Market Report provides comprehensive analysis of plasma collection infrastructure, fractionation technologies, therapeutic applications, and industry supply chains. The report examines plasma collection volumes exceeding 60 million liters annually and analyzes the operational structure of more than 900 plasma collection centers worldwide. It evaluates over 40 plasma fractionation facilities that collectively process millions of liters of plasma for production of immunoglobulin, albumin, and coagulation factor therapies. The Human Blood Plasma Fractionation Market Research Report includes detailed analysis of therapeutic demand across immunology, neurology, and hematology segments. Immunoglobulin therapy accounts for approximately 55% of plasma-derived medicine utilization while albumin contributes nearly 25% and clotting factors represent approximately 15%. The report also examines clinical treatment populations including approximately 6 million patients diagnosed with primary immunodeficiency diseases and nearly 400000 individuals suffering from hemophilia worldwide.

The Human Blood Plasma Fractionation Industry Report also analyzes global plasma donation systems including plasmapheresis programs where donors can donate plasma up to 104 times annually. These programs supply nearly 70% of global plasma collection volume. The report evaluates plasma fractionation technologies including ethanol precipitation and chromatography purification systems capable of achieving plasma protein recovery rates exceeding 85%. Regional analysis included in the Human Blood Plasma Fractionation Market Outlook evaluates plasma collection and fractionation capacity across North America, Europe, Asia-Pacific, and Middle East & Africa. North America contributes approximately 70% of global plasma supply while Europe represents nearly 20% and Asia-Pacific contributes approximately 8%. The report also examines healthcare infrastructure supporting plasma-derived therapeutic administration across more than 250000 hospitals and specialized treatment centers worldwide.